Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Biomea Fusion Inc. Common Stock
BMEA | US
1.41
USD-0.09
-6.00%
BMEA | US
About Biomea Fusion Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
12/03/2026
Close
1.41
Open
1.46
High
1.47
Low
1.40
Biomea Fusion Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219 an orally bioavailable potent and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion Inc. was incorporated in 2017 and is headquartered in Redwood City California.
View LessBMEA | US
Risk
60.7
Sharpe
-0.40
Luna's Score
42/100
Recommendation
Sell
Luna says (BMEA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
57.0%1 month
60.7%3 months
71.4%6 months
95.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.98
Debt to equity
0.10
Debt to assets
0.08
Ent. to EBITDA
-3.75
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-146.72M
MarketCap
51.06M
MarketCap(USD)
51.06M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-85.09
Short ratio
9.35
Short perc.
35.67
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.34
Range1M
0.40
Range3M
0.63
Volumes: Market Activity
Rel. volume
0.86
Price X volume
1.06M
